MedTrace Logo

Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery

NCT05950152 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2023-07-18

No results posted yet for this study

Summary

The purpose of this study is to determine the analgesic efficacy and safety of Meloxicam Injection in subjects undergoing abdominal surgery.

Conditions

  • Pain, Post-operative

Interventions

DRUG

Meloxicam Injection 30mg

meloxicam injection 30mg every 24 hours for up to 2 dose

DRUG

Meloxicam Injection 60mg

meloxicam injection 60mg every 24 hours for up to 2 dose

DRUG

Nacl 0.9%

IV Placebo every 24 hours for up to 2 doses

Sponsors & Collaborators

  • The Third Xiangya Hospital of Central South University

    collaborator OTHER

  • Beijing Tide Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2023-12-31
Completion
2024-02-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05950152 on ClinicalTrials.gov